Clinical Trials Logo

Varicella clinical trials

View clinical trials related to Varicella.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06068608 Not yet recruiting - Varicella Clinical Trials

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

Start date: October 5, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to evaluate the safety and tolerability of TNM005 following a single dose by intramuscular (IM) administration in healthy adult subjects The main questions it aims to answer are:1. safety profileļ¼›2. PK properties 3. PD properties

NCT ID: NCT05952505 Not yet recruiting - Clinical trials for SARS-CoV-2 Infection

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

Start date: August 2023
Phase: Phase 4
Study type: Interventional

Eligible participants were randomly assigned (1:1:1), using block randomization stratified, to either 3 groups. Group 1 will be immunized inactivated SARS-CoV-2 vaccine and varicella vaccine in day 0 followed by measles-mumps-rubella vaccine(MMR) in day 28. Group 2 will be immunized varicella vaccine in day 0 followed by SARS-CoV-2 vaccine and MMR in day 28. Group 3 will be immunized inactivated SARS-CoV-2 vaccine in day 0 followed by MMR and varicella vaccine in day 28. Vaccines were administered 28 days apart, with blood samples taken on day 0 and day 28 before vaccination, and on day 56. Local and systemic symptoms and serious adverse events following immunzation were collected.

NCT ID: NCT00926419 Not yet recruiting - Varicella Clinical Trials

Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery

InjHepAVar
Start date: June 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to assess immunogenicity and safety of nd influence of the delivery system (needle-free injector or syringe with needle) of fractional doses (dose sparing) of two vaccines (Varicella and Hepatitis A vaccines) in children aged 13 to 30 months.